论文部分内容阅读
目的:观察BP素治疗中晚期肝癌患者的血清VEGF水平及肿瘤结节的大小变化。方法:以慢性病毒性肝炎、健康体检者为对照组,中晚期肝癌患者为实验组,采集实验组及对照组患者外周静脉血,分离血清,VEGF测定的步骤及结果计算按试剂盒说明书进行。并同时应用核磁或彩超检查检测患者应用BP素治疗前后肝癌结节的大小变化。结果:肝癌患者血清VEGF水平明显高于健康人群、慢性病毒性肝炎患者组(P<0.01)。UICCI期组和对照组比较有显著性差异(P<0.01),并随肝癌临床病理分期的上升而明显增加。,肝癌患者经治疗后血清VEGF水平明显下降(P<0.05),治疗组肝癌结节较前明显缩小。结论:血清VEGF在应用BP素治疗的肝癌患者血清中的表达存在明显差异,应用BP素治疗可使肝癌结节体积明显缩小,对肝癌的预后、疗效评估等有重要意义,可为中晚期肝癌患者的诊治提供参考性指标。
Objective: To observe the changes of serum VEGF and the size of tumor nodules in patients with advanced liver cancer treated with BP. Methods: Chronic viral hepatitis and healthy subjects were taken as control group. Patients with advanced hepatocellular carcinoma were selected as experimental group. Peripheral venous blood was collected from patients in experimental group and control group. The serum VEGF was determined. The calculation of VEGF and calculation of results were performed according to kit instructions. At the same time the application of nuclear magnetic or color Doppler ultrasound examination of patients with BP before and after treatment of liver cancer nodules size changes. Results: The serum level of VEGF in patients with liver cancer was significantly higher than that in healthy people and patients with chronic viral hepatitis (P <0.01). There was significant difference between UICCI group and control group (P <0.01), and increased with the clinicopathological stage of HCC. , The serum level of VEGF in patients with hepatocellular carcinoma after treatment was significantly decreased (P <0.05), the treatment group, liver cancer nodules was significantly reduced compared with the previous. Conclusions: Serum VEGF expression in serum of patients with hepatocellular carcinoma treated with BP is significantly different. The application of BP can significantly reduce the volume of liver cancer, and is of great significance for the prognosis and curative effect of hepatocellular carcinoma. The diagnosis and treatment of patients provide reference indicators.